Business Wire

AL-ADTRAN

17.5.2022 11:32:12 CEST | Business Wire | Press release

Share
Fibernet Builds Competitive 10G Fiber Network with Adtran

Adtran, Inc. , (NASDAQ: ADTN), the leading provider of next-generation multi-gigabit fiber access and fiber extension solutions, today announced Fibernet is leveraging the Adtran 10G Fiber Access Platform to build an XGS-PON fiber network that will connect 50,000 customers in its first phase. Fibernet is leveraging its innovative fiber trenching technology to quickly build a fiber network and is using Adtran’s reliable 10G solutions to deploy competitive, scalable broadband services to households and businesses in Finland.

Fibernet is a new alternative network provider (altnet) in Finland, where much of the country can access 4G mobile broadband coverage. However, increased demand for high-bandwidth, reliable internet means that fiber connections are a necessity. While some established service providers began slowly building expensive fiber networks, Fibernet invested in an innovative fiber trenching approach that allows the altnet to build its network much faster. Fibernet selected the Adtran 10G Fiber Access Platform as its foundation to launch high-quality, competitive broadband services for internet, IPTV, telehealth and more.

“While Fibernet is new to this market, our leaders have deep experience in implementing superior broadband networks. We selected Adtran because of its experience in both the fiber access and altnet markets, and together we make a great team. We are extremely pleased with the support that Adtran has provided in our startup phase,” said Janne Ahola, CEO at Fibernet. “We understand that fiber is the only way to supply fast and reliable network connections that can scale with subscriber demands. Adtran provides a solution that can help us meet those needs today and in the future.”

The Adtran 10G Fiber Access Platform leverages the symmetrical upload and download speeds of XGS-PON technology, which future-proofs the network against growing demand for high-bandwidth cloud and streaming services. Adtran’s supply availability is also a differentiator for Fibernet. In Finland, the ground is frozen for five months each year. The long winters require well-planned building seasons and hardware deliveries must be on schedule during the warmer months. Adtran offers a comprehensive end-to-end access portfolio that allows Fibernet to order most of the hardware from a single vendor to better ensure on-time deliveries.

“Fibernet has a key advantage with its micro-trenching technology that lets it build its fiber network much faster. With Adtran in its network, Fibernet can match that innovation with a 10G fiber access platform that will provide reliable, high-quality services today and grow with them as subscriber demands evolve,” said Stuart Broome, Vice President of Sales, EMEA at Adtran. “The ease of scalability will enable Fibernet to increase capacity and scale services beyond its traditional residential subscriber base to support the connectivity needs of local small- and mid-sized businesses as well.”

For more information about the Adtran 10G Fiber Access Platform , visit www.adtran.com/fiber-access .

About Adtran

Adtran, Inc. is a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are currently in use by service providers, private enterprises, government organizations and millions of individual users worldwide. Find more at Adtran , LinkedIn and Twitter .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release

Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into

U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release

Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted

Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release

Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,

Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release

Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye